IN2014MN02104A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02104A IN2014MN02104A IN2104MUN2014A IN2014MN02104A IN 2014MN02104 A IN2014MN02104 A IN 2014MN02104A IN 2104MUN2014 A IN2104MUN2014 A IN 2104MUN2014A IN 2014MN02104 A IN2014MN02104 A IN 2014MN02104A
- Authority
- IN
- India
- Prior art keywords
- hydroxyacrylamide
- dihydro
- oxo
- ethyl
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261622127P | 2012-04-10 | 2012-04-10 | |
| PCT/US2013/035004 WO2013154870A1 (en) | 2012-04-10 | 2013-04-02 | Histone deacetylases (hdacs) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02104A true IN2014MN02104A (xx) | 2015-09-04 |
Family
ID=49292802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2104MUN2014 IN2014MN02104A (xx) | 2012-04-10 | 2013-04-02 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9387209B2 (xx) |
| EP (1) | EP2836484B1 (xx) |
| JP (1) | JP6258918B2 (xx) |
| KR (1) | KR101781922B1 (xx) |
| CN (1) | CN104364237B (xx) |
| AU (1) | AU2013246278B2 (xx) |
| BR (1) | BR112014025122B1 (xx) |
| ES (1) | ES2630062T3 (xx) |
| IL (1) | IL235053A (xx) |
| IN (1) | IN2014MN02104A (xx) |
| RU (1) | RU2629947C2 (xx) |
| TW (1) | TWI481597B (xx) |
| WO (1) | WO2013154870A1 (xx) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102014492B1 (ko) | 2011-09-12 | 2019-08-26 | 어플라이드 머티어리얼스, 인코포레이티드 | 복합 플라스틱 부분들을 구비한 캐리어 헤드 |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG11201602445SA (en) | 2013-10-04 | 2016-04-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP2017508798A (ja) * | 2014-03-07 | 2017-03-30 | ザ ジョンズ ホプキンス ユニバーシティ | ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤 |
| WO2015143012A1 (en) | 2014-03-19 | 2015-09-24 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| WO2015153516A1 (en) * | 2014-04-04 | 2015-10-08 | University Of Florida Research Foundation | Hdac inhibitor compounds and methods of treatment |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| CN108349985A (zh) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| KR102576274B1 (ko) * | 2017-05-16 | 2023-09-07 | 안지 파마슈티컬 코퍼레이션 리미티드 | 히스톤 데아세틸라제(hdac) 저해제 |
| GB201918404D0 (en) * | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of aplha1-antitrypsin deficiency |
| KR20210116830A (ko) * | 2020-03-17 | 2021-09-28 | 충북대학교 산학협력단 | 신규한 4-옥소퀴나졸린-기반 n-하이드록시프로펜아미드 및 이의 용도 |
| CN111517977B (zh) * | 2020-05-28 | 2023-05-23 | 爱斯特（成都）生物制药股份有限公司 | 一种合成2,4-二氟-3-三甲基乙酰胺基苯甲酸的方法 |
| US20230212129A1 (en) | 2020-06-08 | 2023-07-06 | Annji Pharmaceutical Co., Ltd. | Quinazoline derivatives useful as selective hdac6 inhibitors |
| WO2023159155A1 (en) * | 2022-02-18 | 2023-08-24 | Pivalent Therapeutics, Inc. | Inhibitors of phosphoinositide 3-kinase (pi3k) and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH464935A (de) * | 1965-05-12 | 1968-11-15 | Sumitomo Chemical Co | Verfahren zur Herstellung neuer Chinazolinonderivate |
| FR6001M (xx) * | 1966-12-02 | 1968-04-29 | ||
| ZA705270B (en) * | 1969-08-02 | 1971-04-28 | Sumitomo Chemical Co | Novel quinazolinone derivatives and a process for production thereof |
| US4054658A (en) * | 1974-02-06 | 1977-10-18 | William H. Rorer, Inc. | Therapeutic compositions containing methaqualone |
| NZ192392A (en) | 1978-12-19 | 1983-02-15 | M Ishikawa | 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones |
| JP3488890B2 (ja) * | 1993-11-09 | 2004-01-19 | アグロカネショウ株式会社 | ３−ｎ−置換キナゾリノン誘導体、その製造法および該化合物を含有する除草剤 |
| EP1280764B1 (en) * | 2000-03-24 | 2010-11-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| EP1524262A1 (en) * | 2000-03-24 | 2005-04-20 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| JP2006512315A (ja) * | 2002-11-04 | 2006-04-13 | エヌピーエス ファーマスーティカルズ インコーポレイテッド | カルシリティックとしてのキナゾリノン化合物 |
| ITMI20041869A1 (it) | 2004-10-01 | 2005-01-01 | Dac Srl | Nuovi inibitori delle istone deacetilasi |
| US20070032502A1 (en) * | 2005-07-15 | 2007-02-08 | Schering Corporation | Quinazoline derivatives useful in cancer treatment |
| JP5305909B2 (ja) | 2005-09-21 | 2013-10-02 | フォーエスシー アクチエンゲゼルシャフト | ヒストンデアセチラーゼインヒビターとしてのスルホニルピロール塩酸塩 |
| GB0525068D0 (en) * | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GB0624187D0 (en) | 2006-12-04 | 2007-01-10 | Jackson William P | HDAC inhibitors |
| WO2008087514A2 (en) | 2007-01-17 | 2008-07-24 | Orchid Research Laboratories Limited | Hdac inhibitors |
| EP2190845A2 (en) | 2007-08-21 | 2010-06-02 | ArQule, Inc. | Hdac inhibitors |
| AU2008307541B2 (en) | 2007-10-01 | 2015-02-12 | Lixte Biotechnology, Inc. | HDAC inhibitors |
| US8431538B2 (en) | 2009-07-22 | 2013-04-30 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods of using same |
-
2013
- 2013-04-02 US US13/855,525 patent/US9387209B2/en active Active
- 2013-04-02 AU AU2013246278A patent/AU2013246278B2/en active Active
- 2013-04-02 ES ES13775887.6T patent/ES2630062T3/es active Active
- 2013-04-02 WO PCT/US2013/035004 patent/WO2013154870A1/en active Application Filing
- 2013-04-02 EP EP13775887.6A patent/EP2836484B1/en active Active
- 2013-04-02 CN CN201380030630.7A patent/CN104364237B/zh active Active
- 2013-04-02 KR KR1020147031519A patent/KR101781922B1/ko active IP Right Grant
- 2013-04-02 BR BR112014025122-3A patent/BR112014025122B1/pt active IP Right Grant
- 2013-04-02 RU RU2014144142A patent/RU2629947C2/ru active
- 2013-04-02 JP JP2015505789A patent/JP6258918B2/ja active Active
- 2013-04-02 IN IN2104MUN2014 patent/IN2014MN02104A/en unknown
- 2013-04-10 TW TW102112723A patent/TWI481597B/zh active
-
2014
- 2014-10-07 IL IL235053A patent/IL235053A/en active IP Right Grant
-
2015
- 2015-03-23 US US14/666,169 patent/US9155739B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014144142A (ru) | 2016-06-10 |
| BR112014025122B1 (pt) | 2022-08-16 |
| JP6258918B2 (ja) | 2018-01-10 |
| US20130267542A1 (en) | 2013-10-10 |
| AU2013246278B2 (en) | 2016-11-03 |
| TWI481597B (zh) | 2015-04-21 |
| RU2629947C2 (ru) | 2017-09-05 |
| EP2836484A4 (en) | 2015-09-02 |
| EP2836484B1 (en) | 2017-06-14 |
| KR101781922B1 (ko) | 2017-09-26 |
| CN104364237A (zh) | 2015-02-18 |
| EP2836484A1 (en) | 2015-02-18 |
| KR20150000901A (ko) | 2015-01-05 |
| US9155739B2 (en) | 2015-10-13 |
| BR112014025122A2 (pt) | 2021-07-06 |
| ES2630062T3 (es) | 2017-08-17 |
| AU2013246278A1 (en) | 2014-11-13 |
| CN104364237B (zh) | 2016-08-24 |
| US20150196563A1 (en) | 2015-07-16 |
| TW201345898A (zh) | 2013-11-16 |
| WO2013154870A1 (en) | 2013-10-17 |
| US9387209B2 (en) | 2016-07-12 |
| IL235053A (en) | 2017-09-28 |
| JP2015512939A (ja) | 2015-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02104A (xx) | ||
| WO2012173682A3 (en) | Compounds and methods for the treatment of isocitrate dehydrognase related diseases | |
| PH12015502658A1 (en) | 3,4-dihydroisoquinolin-2 (1h)-yl compounds | |
| DOP2016000124A (es) | Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo | |
| MX2017013801A (es) | Métodos para tratar el cáncer. | |
| CR20140413A (es) | Inhibidores de serina/treonina cinasa | |
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| MD20160017A2 (ro) | Polimorf al inhibitorilor SYK | |
| MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
| MX2018001990A (es) | Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac. | |
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| MD4684B1 (ro) | Formulări pe bază de imidazopirazine în calitate de inhibitori SYK | |
| MX2013011591A (es) | Métodos y composiciones para tratar enfermedades neurodegenerativas. | |
| PH12015500587A1 (en) | Combination of regorafenib and acetylsalicylic acid for treating cancer | |
| MX2016008624A (es) | Inhibidores de serina/treonina cinasa. | |
| PH12015501586A1 (en) | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors | |
| MX345780B (es) | Inhibidores triciclicos de girasa. | |
| PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
| IN2012DN02556A (xx) | ||
| BR112012031340A2 (pt) | derivados de cianoquinolina | |
| MX2013002620A (es) | Novedosas n-hidroxi-benzamidas para el tratamiento del cancer. | |
| PH12014502747A1 (en) | Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide | |
| WO2014163622A8 (en) | Multifunctional quinoline derivatives as anti-neurodegenerative agents | |
| WO2014160177A3 (en) | Quinazoline inhibitors of pi3k |